Trial
NCT04406272
VB-111 in Surgically Accessible Recurrent/Progressive GBM
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Vascular Biogenics Ltd. operating as VBL Therapeutics
Condition
Glioblastoma
Intervention
VB11
Why stopped
Trial stopped at request of VBL Therapeutics, as they are no longer pursuing their VB-111 development program.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-10